CSL Limited: Angioedemas, Hereditary trials

The registry lists 14 Angioedemas, Hereditary studies with CSL Limited as lead sponsor. 2 are open to participants now and 9 have results posted.

Phase 1 2Phase 2 3Phase 3 7Phase 4 1No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Post Study Access of CSL312 (Garadacimab) for Pediatric Participants With Hereditary Angioedema Who Have Completed the CSL312_3003 StudyAvailableNCT07159464
• A Study Investigating the Effectiveness and Safety of Garadacimab for Treating Patients With Hereditary Angioedema (HAE)RecruitingNCT07001280
• CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary AngioedemaCompletedNCT05819775Phase 3Results posted
• Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema AttacksCompletedNCT04739059Phase 3Results posted
• CSL312 (Garadacimab) in the Prevention of Hereditary Angioedema AttacksCompletedNCT04656418Phase 3Results posted
• A Study to Investigate CSL312 in Subjects With Hereditary Angioedema (HAE)CompletedNCT03712228Phase 2Results posted
• A Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary AngioedemaCompletedNCT02316353Phase 3Results posted
• A Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary AngioedemaCompletedNCT01912456Phase 3Results posted
• A Study to Evaluate the Clinical Pharmacology and Safety of C1-esterase Inhibitor Administered by the Subcutaneous RouteCompletedNCT01576523Phase 1/2Results posted
• C1 Esterase Inhibitor in Hereditary Angioedema (HAE)(Extension Study)CompletedNCT00292981Phase 3Results posted
• Human C1 Esterase Inhibitor (C1-INH) in Subjects With Acute Abdominal or Facial Hereditary Angioedema (HAE) AttacksCompletedNCT00168103Phase 2/3Results posted
• Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching to GaradacimabCompletedNCT06806657Phase 4
• A Study to Evaluate the Safety and Pharmacokinetics of Two Formulations of C1-esterase InhibitorCompletedNCT01760343Phase 1
• Patient Registry Study of Berinert® in Normal Clinical PracticeCompletedNCT01108848